12/19
09:16 am
vstm
Verastem, Inc. (NASDAQ: VSTM) had its price target raised by analysts at Mizuho from $7.00 to $9.00. They now have an "outperform" rating on the stock.
Medium
Report
Verastem, Inc. (NASDAQ: VSTM) had its price target raised by analysts at Mizuho from $7.00 to $9.00. They now have an "outperform" rating on the stock.
12/19
08:10 am
vstm
Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
12/18
07:36 am
vstm
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer [Yahoo! Finance]
Medium
Report
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer [Yahoo! Finance]
12/18
07:30 am
vstm
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Medium
Report
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
11/26
07:00 am
vstm
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
Medium
Report
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
11/20
12:04 am
vstm
Verastem, Inc. (NASDAQ: VSTM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Verastem, Inc. (NASDAQ: VSTM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/6
05:06 pm
vstm
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates [Yahoo! Finance]
Medium
Report
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates [Yahoo! Finance]
11/6
04:05 pm
vstm
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Medium
Report
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
11/1
12:18 pm
vstm
Verastem Oncology submits NDA for ovarian cancer treatment [Yahoo! Finance]
Low
Report
Verastem Oncology submits NDA for ovarian cancer treatment [Yahoo! Finance]
10/31
04:01 pm
vstm
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Medium
Report
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
10/31
07:30 am
vstm
Verastem Oncology to Participate in Upcoming Investor Conferences
Low
Report
Verastem Oncology to Participate in Upcoming Investor Conferences
10/18
10:35 am
vstm
Verastem, Inc. (NASDAQ: VSTM) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $13.00 price target on the stock.
High
Report
Verastem, Inc. (NASDAQ: VSTM) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $13.00 price target on the stock.
10/18
08:33 am
vstm
Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
High
Report
Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
10/18
08:33 am
vstm
Verastem, Inc. (NASDAQ: VSTM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
High
Report
Verastem, Inc. (NASDAQ: VSTM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
10/17
01:00 am
vstm
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
High
Report
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
10/9
06:00 am
vstm
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting
Neutral
Report
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting
10/7
07:30 am
vstm
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/30
08:01 am
vstm
Verastem, Inc. (NASDAQ: VSTM) is now covered by analysts at Guggenheim. They set a "buy" rating and a $13.00 price target on the stock.
Medium
Report
Verastem, Inc. (NASDAQ: VSTM) is now covered by analysts at Guggenheim. They set a "buy" rating and a $13.00 price target on the stock.